Top

Current Treatment Options in Gastroenterology

25-09-2024 | Pancreatic Cyst

Pancreatic Cysts in the Geriatric Sphere: A Call for Close Consideration of Patient Characteristics in Pancreatic Cyst Management

Authors: Mahip Grewal, Tamas A. Gonda

Published in: Current Treatment Options in Gastroenterology

Abstract

Purpose of Review

Increasing use of high-quality abdominal imaging has been associated with a rise in the detection of pancreatic cysts. The incidence of intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cyst type, increases with age. The purpose of this review is to present a framework for management, whereby care is tailored according to the risk of the cyst, patient characteristics, and patient preferences.

Recent Findings

Studies have shown that the cumulative incidence of pancreatic cancer rises over time for patients with IPMNs. Nonetheless, small branch-duct IPMNs constitute the majority of identified cysts in older patients, and growing data suggest that there is a low-risk of malignant transformation for such cysts that exhibit stability over 5 years. Moreover, cohort studies of older patients with IPMNs have reported a low incidence of pancreatic cancer.

Further, while there have been studies of pancreatic cyst outcomes stratified by age and comorbidity burden, an additional patient characteristic worth addressing is frailty, which has been associated with outcomes for cirrhosis and inflammatory bowel disease.

Summary

Most pancreatic cysts identified in older adults will not progress to pancreatic cancer. Thus, a multidisciplinary approach, in which management is guided by both the cyst risk and patient’s overall preferences and prognosis, should be employed to achieve patient-centered care.

Kromrey ML, Bülow R, Hübner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67(1):138–45. https://doi.org/10.1136/gutjnl-2016-313127.CrossRefPubMed

de la Fuente J, Chatterjee A, Lui J, et al. Long-term outcomes and risk of pancreatic cancer in intraductal papillary mucinous neoplasms. JAMA Netw Open. 2023;6(10):e2337799. https://doi.org/10.1001/jamanetworkopen.2023.37799.CrossRefPubMedPubMedCentral

Skou ST, Mair FS, Fortin M, et al. Multimorbidity. Nat Rev Dis Primers. 2022;8(1):48. Published 2022 Jul 14. https://doi.org/10.1038/s41572-022-00376-4

Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269–76. https://doi.org/10.1001/archinte.162.20.2269.CrossRefPubMed

Lochner KA, Cox CS. Prevalence of multiple chronic conditions among Medicare beneficiaries, United States, 2010. Prev Chronic Dis. 2013;10:E61. https://doi.org/10.5888/pcd10.120137.CrossRefPubMedPubMedCentral

Sharib J, Esserman L, Koay EJ, et al. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective. Surgery. 2020;168(4):601–9. https://doi.org/10.1016/j.surg.2020.04.052.CrossRefPubMed

Lobo JM, Scheiman JM, Zaydfudim VM, Shami VM, Sauer BG. Clinical and economic outcomes of patients undergoing guideline-directed management of pancreatic cysts. Am J Gastroenterol. 2020;115(10):1689–97.CrossRefPubMed

van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, van Hooft JE, Besselink MG. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat Rev Gastroenterol Hepatol. 2019;16(11):676–89. https://doi.org/10.1038/s41575-019-0195-x.CrossRefPubMed

Farrell JJ. Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions. Gut Liver. 2015;9(5):571–89. https://doi.org/10.5009/gnl15063.CrossRefPubMedPubMedCentral

10.

Tjaden C, Sandini M, Mihaljevic AL, et al. Risk of the watch-and-wait concept in surgical treatment of intraductal papillary mucinous neoplasm. JAMA Surg. 2021;156(9):818–25. https://doi.org/10.1001/jamasurg.2021.0950.CrossRefPubMedPubMedCentral

11.

Marchegiani G, Pollini T, Burelli A, et al. Surveillance for presumed BD-IPMN of the pancreas: Stability, size, and age identify targets for discontinuation. Gastroenterology. 2023;165(4):1016-1024.e5. https://doi.org/10.1053/j.gastro.2023.06.022.CrossRefPubMed

12.

Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024;24(2):255–70. https://doi.org/10.1016/j.pan.2023.12.009.CrossRefPubMed

13.

Hasan A, Visrodia K, Farrell JJ, Gonda TA. Overview and comparison of guidelines for management of pancreatic cystic neoplasms. World J Gastroenterol. 2019;25(31):4405–13. https://doi.org/10.3748/wjg.v25.i31.4405.CrossRefPubMedPubMedCentral

14.

Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1–2):17–32. https://doi.org/10.1159/000090023.CrossRefPubMed

15.

Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97. https://doi.org/10.1016/j.pan.2012.04.004.CrossRefPubMed

16.

Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53. https://doi.org/10.1016/j.pan.2017.07.007.CrossRefPubMed

17.

Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology. 2020;158(1):226-237.e5. https://doi.org/10.1053/j.gastro.2019.08.032.CrossRefPubMed

18.

Kazmi SZ, Jung HS, Han Y, et al. Systematic review on surveillance for non-resected branch-duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2024;24(3):463–88. https://doi.org/10.1016/j.pan.2024.02.015.CrossRefPubMed

19.

Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG clinical guideline: Diagnosis and management of pancreatic cysts. Am J Gastroenterol. 2018;113(4):464–79. https://doi.org/10.1038/ajg.2018.14.CrossRefPubMed

20.

Khannoussi W, Vullierme MP, Rebours V, et al. The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2012;12(3):198–202. https://doi.org/10.1016/j.pan.2012.03.056.CrossRefPubMed

21.

Kwong WT, Hunt GC, Fehmi SM, et al. Low rates of malignancy and mortality in asymptomatic patients with suspected neoplastic pancreatic cysts beyond 5 years of surveillance. Clin Gastroenterol Hepatol. 2016;14(6):865–71. https://doi.org/10.1016/j.cgh.2015.11.013.CrossRefPubMed

22.

Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2016;315(23):2576–94. https://doi.org/10.1001/jama.2016.3332.CrossRefPubMed

23.

European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. https://doi.org/10.1136/gutjnl-2018-316027.CrossRef

24.

Sahora K, Ferrone CR, Brugge WR, et al. Effects of comorbidities on outcomes of patients with intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2015;13(10):1816–23. https://doi.org/10.1016/j.cgh.2015.04.177.CrossRefPubMed

25.

Crippa S, Pezzilli R, Bissolati M, et al. Active surveillance beyond 5 years is required for presumed branch-duct intraductal papillary mucinous neoplasms undergoing non-operative management. Am J Gastroenterol. 2017;112(7):1153–61. https://doi.org/10.1038/ajg.2017.43.CrossRefPubMed

26.

Lawrence SA, Attiyeh MA, Seier K, et al. Should patients with cystic lesions of the pancreas undergo long-term radiographic surveillance?: results of 3024 patients evaluated at a single institution. Ann Surg. 2017;266(3):536–44. https://doi.org/10.1097/SLA.0000000000002371.CrossRefPubMed

27.

Del Chiaro M, Ateeb Z, Hansson MR, et al. Survival analysis and risk for progression of intraductal papillary mucinous neoplasia of the pancreas (IPMN) under surveillance: a single-institution experience. Ann Surg Oncol. 2017;24(4):1120–6. https://doi.org/10.1245/s10434-016-5661-x.CrossRefPubMed

28.

Megibow AJ, Baker ME, Morgan DE, et al. Management of incidental pancreatic cysts: A white paper of the ACR incidental findings committee. J Am Coll Radiol. 2017;14(7):911–23. https://doi.org/10.1016/j.jacr.2017.03.010.CrossRefPubMed

29.

Das A, Wells CD, Nguyen CC. Incidental cystic neoplasms of pancreas: what is the optimal interval of imaging surveillance? Am J Gastroenterol. 2008;103(7):1657–62. https://doi.org/10.1111/j.1572-0241.2008.01893.x.CrossRefPubMed

30.

Chernyak V, Flusberg M, Haramati LB, Rozenblit AM, Bellin E. Incidental pancreatic cystic lesions: is there a relationship with the development of pancreatic adenocarcinoma and all-cause mortality? Radiology. 2015;274(1):161–9. https://doi.org/10.1148/radiol.14140796.CrossRefPubMed

31.

Vege SS, Ziring B, Jain R, Moayyedi P; Clinical Guidelines Committee; American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):819-quize13. https://doi.org/10.1053/j.gastro.2015.01.015

32.

Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):824-48.e22. https://doi.org/10.1053/j.gastro.2015.01.014.CrossRefPubMed

33.

Weinberg DS, Gatsonis C, Zeh HJ, Carlos RC, O'Dwyer PJ; EA2185 Team. Comparing the clinical impact of pancreatic cyst surveillance programs: a trial of the ECOG-ACRIN cancer research group (EA2185). Contemp Clin Trials. 2020;97:106144. https://doi.org/10.1016/j.cct.2020.106144

34.

Chhoda A, Singh S, Sheth AH, et al. Benefit of extended surveillance of low-risk pancreatic cysts after 5-year stability: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(6):1430–46. https://doi.org/10.1016/j.cgh.2022.04.025.CrossRefPubMed

35.

Marchegiani G, Andrianello S, Perri G, et al. The role of age in pancreatic intraductal papillary mucinous neoplasms of the pancreas: Same risk of death but different implications for management. Dig Liver Dis. 2018;50(12):1327–33. https://doi.org/10.1016/j.dld.2018.06.002.CrossRefPubMed

36.

Anand GS, Youssef F, Liu L, et al. Pancreas cancer incidence and pancreas cancer-associated mortality are low in national cohort of 7211 pancreas cyst patients. Dig Dis Sci. 2022;67(3):1065–72. https://doi.org/10.1007/s10620-021-06923-5.CrossRefPubMed

37.

Kwok K, Chang J, Duan L, Huang BZ, Wu BU. Competing risks for mortality in patients with asymptomatic pancreatic cystic neoplasms: Implications for clinical management. Am J Gastroenterol. 2017;112(8):1330–6. https://doi.org/10.1038/ajg.2017.141.CrossRefPubMed

38.

Ofori-Asenso R, Chin KL, Mazidi M, et al. Global incidence of frailty and prefrailty among community-dwelling older adults: A systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198398. https://doi.org/10.1001/jamanetworkopen.2019.8398.CrossRefPubMedPubMedCentral

39.

Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol. 2017;23(5):899–905. https://doi.org/10.3748/wjg.v23.i5.899.CrossRefPubMedPubMedCentral

40.

Faye AS, Wen T, Soroush A, et al. Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD. Dig Dis Sci. 2021;66(12):4178–90. https://doi.org/10.1007/s10620-020-06746-w.CrossRefPubMedPubMedCentral

41.

Poruk KE, Shahrokni A, Brennan MF. Surgical resection for intraductal papillary mucinous neoplasm in the older population. Eur J Surg Oncol. 2022;48(6):1293–9. https://doi.org/10.1016/j.ejso.2021.12.001.CrossRefPubMed

42.

Kochar B, Ufere NN, Ritchie CS, Lai JC. The 5Ms of geriatrics in gastroenterology: The path to creating age-friendly care for older adults with inflammatory bowel diseases and cirrhosis. Clin Transl Gastroenterol. 2022;13(1):e00445. https://doi.org/10.14309/ctg.0000000000000445.CrossRefPubMedPubMedCentral

43.

Overbeek KA, Kamps A, van Riet PA, et al. Pancreatic cyst surveillance imposes low psychological burden. Pancreatology. 2019;19(8):1061–6. https://doi.org/10.1016/j.pan.2019.08.011.CrossRefPubMed

44.

Cazacu IM, Luzuriaga Chavez AA, Mendoza TR, et al. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Endosc Ultrasound. 2020;9(1):53–8. https://doi.org/10.4103/eus.eus_56_19.CrossRefPubMed

45.

Wundsam HV, Rösch CS, Kirchweger P, et al. Long-term quality of life after pancreatic surgery for intraductal papillary mucinous neoplasm. Eur Surg Res. 2021;62(2):80–7. https://doi.org/10.1159/000515459.CrossRefPubMed

Title: Pancreatic Cysts in the Geriatric Sphere: A Call for Close Consideration of Patient Characteristics in Pancreatic Cyst Management
Authors: Mahip Grewal
Tamas A. Gonda
Publication date: 25-09-2024
Publisher: Springer US
Keywords: Pancreatic Cyst
Pancreatic Cancer
Pancreatic Cancer
Published in: Current Treatment Options in Gastroenterology
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-024-00459-z

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Pancreatic Cysts in the Geriatric Sphere: A Call for Close Consideration of Patient Characteristics in Pancreatic Cyst Management

Abstract

Purpose of Review

Recent Findings

Summary

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials